Strides Pharma Science Limited
Strides Pharma Science Ltd is in the business of development and manufacturing of pharmaceutical products.The company's pharmaceutical products are sold in over 100 countries.The company has always followed an inorganic growth strategy over the years that resulted in foray into new markets, addition of new business segments, therapy segments and manufacturing infrastructure.
What Strides files
- Others53
- Investor Meet35
- Updates32
- Important31
- Board Meeting15
- JV/Acquisition6
Strides Pharma Science Limited has informed the Exchange about completion of USFDA Inspection at the Company s Formulations Facility at Alathur
Strides Pharma's flagship Bengaluru facility received USFDA's Establishment Inspection Report, successfully closing the inspection. This positive regulatory update strengthens Strides' track record, ensuring continued product supply to global markets.
Strides Pharma reported 13% YoY revenue growth to ₹1,265.4 Cr, driven by strong 17% growth in Ex-US markets. EBITDA rose 5.4% to ₹229.8 Cr. Operational PAT hit ₹123.1 Cr. The company also reduced net debt by ₹11.9 Cr and divested Pivot Path, unlocking ₹100 Cr.
Strides Pharma's Q1FY27 revenue rose 13% YoY to ₹1,265.4 Cr, led by 17% Ex-US growth. EBITDA increased 5.4% to ₹229.8 Cr, absorbing ₹13.1 Cr geopolitical costs. The company unlocked ₹100 Cr from Pivot Path divestment and reduced net debt by ₹11.9 Cr.
Strides Pharma reported 3 voluntary product recalls due to quality issues. Exports comprise 90.66% of turnover. Related party transactions are significant at 86.40% of sales and 99.58% of investments. Employee well-being spending dropped to 0.44% of revenue. `2.88 Cr` spent on CSR.